Renishaw Diagnostics signs contract reagent manufacturing agreement with Gen-Probe
21 June 2011
Renishaw Diagnostics Ltd, a world leading provider of trace level detection technologies based on the exploitation of surface enhanced Raman scattering (SERS) and surface enhanced resonance Raman scattering (SERRS) for infectious disease research and molecular diagnostics applications, today announced that it has established a contract reagent manufacturing agreement with Gen-Probe's Cardiff facility.
David Burns, CEO of Renishaw Diagnostics Ltd said, “We are very pleased to have engaged Gen-Probe to manufacture our RenDx molecular diagnostics kits for us under international standards. Gen-Probe has a very successful track record in manufacturing and selling their own nucleic acid based diagnostics kits to high quality manufacturing standards and we selected them as our manufacturing partner of choice for our RenDx reagent kits because of this experience. We are moving our RenDx products into clinical evaluation studies in Europe and the USA for our three multiplex infectious disease panels and it was important to secure manufacturing of these to the standards that will allow us to go for regulatory compliance approvals to market our products in Europe and the USA as certified in-vitro diagnostics products.”
Gen-Probe conforms to Good Manufacturing Practices and has management systems which are certified to ISO 13485:2003 and ISO 9001:2008. Dr. Molly Price-Jones, Senior Director of the Gen-Probe Cardiff site, said, “We are delighted to be providing contract services for Renishaw Diagnostics Ltd to manufacture their in vitro diagnostic kits in our GMP manufacturing facilities in the UK.”
Gen-Probe is a global leader in the development, manufacture and marketing of rapid, accurate and cost-effective nucleic acid tests that are used primarily to diagnose human diseases and screen donated human blood. The reagents for Renishaw Diagnostics will be manufactured in the company's state of the art facilities in the UK, which provide controlled environments for the manufacture of CE marked in vitro diagnostic kits.
About Renishaw Diagnostics Ltd
Renishaw Diagnostics Ltd, formerly D3 Technologies Ltd, was a Strathclyde University spin-out before being acquired by the Renishaw Group, which is a leading global supplier of engineering technologies, medical devices and Raman spectroscopy systems. It is focused on developing and commercialising its first in vitro diagnostic (IVD) and clinical research products, with the goal of establishing Renishaw Diagnostics as the premium provider of automated, multiplex, high sensitivity molecular diagnostics products for the detection of human infectious diseases. The Company is based in Glasgow, Scotland, and further information is available at www.renishawdiagnostics.com.
All images and text copyright Renishaw
Register for news updates
Register for regular news updates from Renishaw